The Global Alzheimer’s Platform Foundation (GAP) and the Alzheimer’s Disease Data Initiative (AD Data Initiative) have released the Bio?Hermes?001 dataset — described as the most comprehensive biomarker dataset in Alzheimer’s research history.
The release of Bio?Hermes?001 marks a pivotal moment in Alzheimer’s research: a first?of?its?kind dataset blending biomarker, cognitive, retinal, and speech data across a deeply diverse cohort.
Now available to scientists worldwide, it promises to accelerate validation of emerging diagnostic tools and spur progress toward earlier diagnosis — potentially benefiting underserved communities and transforming care pathways.
What Makes Bio?Hermes?001 Groundbreaking?
- Contains over 80,000 blood and digital test results from diagnostic tools including digital cognitive tests, retinal exams, speech analysis, and traditional PET imaging.
- Participants are highly diverse, with 24% representing traditionally understudied communities, and include individuals who are cognitively normal, with mild cognitive impairment (MCI), or mild Alzheimer’s disease.
- It provides side?by?side performance comparisons of dozens of Alzheimer’s diagnostic methods.
Why This Matters
- Researchers and developers can now use this rich dataset to validate and advance new blood?based and digital diagnostic tests.
- Portions of the dataset have already supported an FDA application for the first blood?based in vitro diagnostic (IVD) for Alzheimer’s disease.
How to Access the Data
Researchers can request access starting August 1, 2025, through the AD Discovery Portal on AD Workbench.
Dementia Help: https://dementiahelp.io/accelerating-alzheimers-research-the-bio-hermes-001-dataset-is-now-publicly-available/
The dataset is available publicly via the AD Workbench.